ATXI Avenue Therapeutics Inc.: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

avenuetx.com (ATXI) - corporate logo

Avenue Therapeutics (ATXI) focuses on developing advanced emergency treatments for individuals with acute pain and rare nervous system pathologies, relying on government contracts. Share price growth is expected following the announcement of final test results for its intravenous analgesic, while investors have already priced in current losses. This EV/EBITDA chart, with a value of , complements data regarding the company's commitment to bioethics and the sustainability of its laboratory processes.

ATXI (Avenue Therapeutics Inc.) EV/EBITDA Multiple history from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for Avenue Therapeutics, Inc (ATXI)

General company analysis:Avenue Therapeutics ATXI
Manufactured products of Avenue Therapeutics Inc.

The automation of clinical data analysis in neurology reduces costs for Avenue Therapeutics (ATXI), directly impacting operating profit. This metric compares the total enterprise value, including debt load, to EBITDA, reflecting the actual efficiency of capital-intensive assets. By analyzing the EV/EBITDA ratio while accounting for debt and amortization, an investor can distinguish fundamental undervaluation from a "value trap" during shifts in market cycles.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|EV/EBITDA Multiple SAVA (cassavasciences.com)|Business Value to Operating Income Before Depreciation ASRT|Coya Therapeutics Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vistagen.com VTGN|Ovid Therapeutics Inc. (OVID) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Acumen Pharmaceuticals, Inc (ABOS) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc.|Alterity Therapeutics (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CLNN|PEPG - Company Value to EBITDA|EV/EBITDA Multiple JUNS (Jupiter Neurosciences, Inc.)|RLMD - Enterprise Value to EBITDA Ratio|ANVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Grace Therapeutics (GRCE)|AIFF: EV/EBITDA Multiple|ANEW Medical, Inc. (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd.|RVPH: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MTVA|EV/EBITDA Multiple NeurAxis (NRXS)|Helius Medical Technologies, Inc. - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio, Inc. (PASG)|Neuphoria - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation NERV (Minerva)|ATHA: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ADXN|Enterprise Value to EBITDA Ratio ALZN|Company Value to EBITDA Cyclerion Therapeutics CYCN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protagenic Therapeutics (PTIX)|EV/EBITDA Multiple Pasithea Therapeutics Corp (KTTA)|Cortigent, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)